- Home
- PHYS vs EXEL Comparison
PHYS vs EXEL Comparison
Compare PHYS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHYS
- EXEL
- Stock Information
- Founded
- PHYS N/A
- EXEL 1994
- Country
- PHYS
- EXEL United States
- Employees
- PHYS N/A
- EXEL N/A
- Industry
- PHYS
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHYS
- EXEL Health Care
- Exchange
- PHYS NYSE
- EXEL Nasdaq
- Market Cap
- PHYS 8.9B
- EXEL 9.4B
- IPO Year
- PHYS N/A
- EXEL 2000
- Fundamental
- Price
- PHYS $24.10
- EXEL $36.92
- Analyst Decision
- PHYS
- EXEL Buy
- Analyst Count
- PHYS 0
- EXEL 18
- Target Price
- PHYS N/A
- EXEL $37.59
- AVG Volume (30 Days)
- PHYS N/A
- EXEL 2.7M
- Earning Date
- PHYS N/A
- EXEL 04-29-2025
- Dividend Yield
- PHYS N/A
- EXEL N/A
- EPS Growth
- PHYS N/A
- EXEL 170.77
- EPS
- PHYS N/A
- EXEL 1.76
- Revenue
- PHYS N/A
- EXEL $2,168,701,000.00
- Revenue This Year
- PHYS N/A
- EXEL $5.45
- Revenue Next Year
- PHYS N/A
- EXEL $10.32
- P/E Ratio
- PHYS N/A
- EXEL $20.98
- Revenue Growth
- PHYS N/A
- EXEL 18.50
- 52 Week Low
- PHYS N/A
- EXEL $20.14
- 52 Week High
- PHYS N/A
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- PHYS 73.61
- EXEL 50.71
- Support Level
- PHYS $23.29
- EXEL $36.71
- Resistance Level
- PHYS $23.50
- EXEL $38.41
- Average True Range (ATR)
- PHYS 0.18
- EXEL 1.04
- MACD
- PHYS 0.04
- EXEL -0.17
- Stochastic Oscillator
- PHYS 94.41
- EXEL 47.50
About PHYS SPROTT PHYSICAL GOLD TRUST
Sprott Physical Gold Trust is a closed-end mutual fund trust. The company provides a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical gold bullion without the inconvenience associated with direct investment in physical gold bullion. The company invests mainly in long-term holdings of unencumbered, fully allocated, physical gold bullion and does not and will not speculate about short-term changes in gold prices.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.